Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN3017 (DuoBody-CD3xCD30) in Relapsed or Refractory CD30+ Lymphoma
2023-503348-15-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Nov 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of gen3017 in classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma (NHL), sponsored by Genmab. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), Incidence and severity of adverse events (AEs) and 1 more. Started Nov 2023; status: completed.
02
Drugs
gen3017
03
Conditions
classical Hodgkin lymphoma (cHL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2023-503348-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503348-15-00.